The Business Of Biotech Podcast
-
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics
2/9/2025
From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies.
-
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience
1/29/2025
From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way.
-
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
1/26/2025
The Business of Biotech welcomes Dr. Jim Doherty of Acumen Pharmaceuticals to discuss the challenges and advances in Alzheimer's treatment, including controversies around amyloid-targeting drugs and the role of biomarkers in personalized therapy.
-
High-Throughput Discovery With BIOPTIC's Andrey Dobry
1/19/2025
Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and advanced screening are reshaping drug discovery. Learn more about BIOPTIC’s bold vision, the challenges of data access, and overcoming skepticism in the biotech industry.
-
RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.
1/12/2025
In close partnership with Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center.
-
Biotech Story Time With Tal Zaks, M.D. (Part 2)
1/5/2025
Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, an mRNA startup. The episode explores Exsilio's foundation, scientific focus, team recruitment, and its $82 million Series A funding led by Novartis Venture Fund and Delos Capital, with support from prominent investors like OrbiMed, CRISPR Therapeutics, and J.P. Morgan Life Sciences Private Capital.
-
Risk Mitigation With MeiraGTx's Zandy Forbes, Ph.D.
12/30/2024
Zandy Forbes, Ph.D., combines science and finance expertise to manage biotech risk. With a Ph.D. from Oxford, a postdoc fellowship, and over a decade as a Wall Street healthcare investor, she now leads Meira GTx as President & CEO. On Business of Biotech, she discusses how her investment experience informs her approach to biotech leadership.
-
Biotech Story Time With Tal Zaks, M.D. (Part 1)
12/22/2024
Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tune in to the first installment of this two-part episode for insight from the early days of mRNA that you probably haven't heard before.
-
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.
12/15/2024
This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch.
-
Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski
12/8/2024
On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that make the company's contract development and manufacturing relationship with Forge Biologics go.